Showing results (1-10 of 23) with videos related to
Sort By:
Pageof 3
Applied Microbiology and Biotechnology|March 5, 2018
Streptomyces spp. in the biocatalysis toolboxJelena Spasic, Mina Mandic, Lidija Djokic, et al.Journal of Adolescent and Young Adult Oncology|June 22, 2022
Young-Onset Colorectal Cancer in Serbia: Tertiary Cancer Center ExperienceNeda Nikolic, Jelena Spasic, Nemanja Stanic, et al.Journal of Biotechnology|November 12, 2022
Engineering cyanobacterial chassis for improved electron supply toward a heterologous ene-reductaseJelena Spasic, Paulo Oliveira, Catarina Pacheco, et al.Journal of Clinical Medicine|September 13, 2025
Evaluating the Predictive Value of Clinical Factors for Pembrolizumab Efficacy and Safety in Advanced NSCLC with High PD-L1 Expression (TPS ≥ 50%)Fedja Djordjevic, Katarina Ljujic, Nemanja Stanic, et al.Journal of Clinical Pathology|November 24, 2018
<i>TP53</i> and DNA-repair gene polymorphisms genotyping as a low-cost lung adenocarcinoma screening toolMilena Cavic, Jelena Spasic, Ana Krivokuca, et al.Oncotargets and Therapy|September 19, 2017
Durable complete remission of poor performance status metastatic lung adenocarcinoma patient treated with second-line erlotinib: a case reportDragana Jovanovic, Ruza Stevic, Marta Velinovic, et al.Dose-Response : a Publication of International Hormesis Society|August 12, 2022
Evaluation of Clinical and Genetic Determinants of Treatment OutCome In EGFR Mutation Positive Advanced Lung AdenocarcinomaVera Jokic, Katarina Savic-Vujovic, Jelena Spasic, et al.Bioprocess and Biosystems Engineering|September 28, 2015
Immobilization of Escherichia coli cells expressing 4-oxalocrotonate tautomerase for improved biotransformation of β-nitrostyreneLidija Djokic, Jelena Spasic, Sanja Jeremic, et al.Dose-Response : a Publication of International Hormesis Society|July 5, 2022
Low-Cost Genetic and Clinical Predictors of Response and Toxicity of Platinum-Based Chemotherapy in Advanced Non-Small Cell Lung CancerJelena Spasic, Milena Cavic, Nemanja Stanic, et al.Expert Review of Anticancer Therapy|February 19, 2021
Hematological parameters in EGFR-mutated advanced NSCLC patients treated with TKIs: predicting survival and toxicityVera Jokic, Katarina Savic-Vujovic, Jelena Spasic, et al.Pageof 3